Ellison R J, Cancellaro L A
J Clin Pharmacol. 1978 Apr;18(4):210-9. doi: 10.1002/j.1552-4604.1978.tb01595.x.
A four-week double-blind comparison between lorazepam and placebo involving 60 patients with anxiety revealed that lorazepam in a mean dose of approximately 3 mg on a b.i.d. regimen is significantly and clinically more effective than placebo for almost all items of the Global, Hamilton, and 35-Item scales at nearly all evaluation periods. Moreover, lorazapem was associated with a 50% greater improvement rate than was placebo. Except for only one patient who was withdrawn from the study because of severe sedation, lorazepam was well tolerated and did not interact adversely with concomitant nonpsychoactive medication.
一项针对60名焦虑症患者进行的为期四周的氯硝西泮与安慰剂的双盲对比研究表明，在几乎所有评估阶段，每日两次服用平均剂量约3毫克氯硝西泮，在总体、汉密尔顿及35项量表的几乎所有项目上，在临床疗效上都显著优于安慰剂。此外，氯硝西泮的改善率比安慰剂高50%。除了一名因严重镇静作用而退出研究的患者外，氯硝西泮耐受性良好，且与同时服用的非精神活性药物无不良相互作用。
